Yıl: 2021 Cilt: 37 Sayı: 3 Sayfa Aralığı: 239 - 248 Metin Dili: İngilizce DOI: 10.5146/tjpath.2021.01545 İndeks Tarihi: 29-05-2022

Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience

Öz:
Objective: To investigate the prognostic and predictive value of PD-L1 expression in operated non-small cell lung cancer (NSCLC) patients and to analyze its relationship with clinicopathological factors. Material and Method: A total of 90 patients with operable NSCLC were included in this retrospective single center study. Tumor blocks of patients were stained immunohistochemically with PD-L1 polyclonal antibody. When evaluated immunohistochemically and statistically, patients with tumor staining percentage of ≥5%, those with +2 and +3 membranous staining intensity, and those with ≥50% H-Score were considered positive. The relationship between PD-L1 expression status and clinicopathological features in addition to the prognostic effect of PD-L1 on survival were statistically analyzed. Results: The frequency of PD-L1 expression was 37%, 15% and 5% according to the staining percentage, staining intensity, and the H-Score, respectively. There was no significant relationship between PD-L1 expression and age, gender, smoking, tumor stage and histological subtype (p> 0.05). However, PD-L1 expression was relatively higher in patients <65 years of age, men, smokers, patients with advanced tumor stage, and squamous cell subtype. Based on the analysis of the H-Score, no significant difference was noted regarding disease-free survival time between PD-L1 positive and PD-L1 negative patients (median 20 [95% CI 1.2-38.7] months vs. median 27 [95% CI 17.5-36] months, p=0.208). However, overall survival time was significantly shorter in PD-L1 positive compared to PD-L1 negative patients (median 24 months [95% CI 9.9-38] vs. median 48 months [95% CI 33.6-62.3], p=0.049). Conclusion: In patients with high PD-L1 expression, the biological behavior of the cancer was more aggressive, and the life expectancy was shorter. PD-L1 expression seems to be a poor prognostic marker in NSCLC patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2020;41:1-24.
  • 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
  • 3. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol. 2005;23:3235-42.
  • 4. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
  • 5. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases- -elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-25.
  • 6. Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171-86.
  • 7. Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel- Plucinska N, Grzegrzolka J, Podhorska-Okolow M, Dziegiel P, Nowinska K. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20:824.
  • 8. Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ, Lu ZY, Fang YC, Chen XF, Liu GT. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis. Eur J Surg Oncol. 2015;41:450-6.
  • 9. Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-39.
  • 10. Hwang JK, Page BJ, Flynn D, Passmore L, McCaul E, Brady J, Yang IA, Marshall H, Windsor M, Bowman RV, Naidoo R, Guan T, Philpot S, Blake ME, Fong KM. Validation of the eighth edition tnm lung cancer staging system. J Thorac Oncol. 2020;15:649-54.
  • 11. Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, Lopez-Rios F, Jain D, Chou TY, Motoi N, Kerr KM, Yatabe Y, Brambilla E, Longshore J, Papotti M, Sholl LM, Thunnissen E, Rekhtman N, Borczuk A, Bubendorf L, Minami Y, Beasley MB, Botling J, Chen G, Chung JH, Dacic S, Hwang D, Lin D, Moreira A, Nicholson AG, Noguchi M, Pelosi G, Poleri C, Travis W, Yoshida A, Daigneault JB, Wistuba, II, Mino-Kenudson M. PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee. J Thorac Oncol. 2020;15:499-519.
  • 12. D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, Crinò L, Terracciano L, Cappuzzo F. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112:95-102.
  • 13. Lin C, Chen X, Li M, Liu J, Qi X, Yang W, Zhang H, Cai Z, Dai Y, Ouyang X. Programmed death-ligand 1 expression predicts tyrosine kinase inhibitor response and better prognosis in a cohort of patients with epidermal growth factor receptor mutation-positive lung adenocarcinoma. Clin Lung Cancer. 2015;16:e25-35.
  • 14. Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen- Corish M, Yip P, Yu B, O’Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. Lung Cancer. 2015;89:181-8.
  • 15. Chen YB, Mu CY, Huang JA. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: A 5-year-follow-up study. Tumori. 2012;98:751-5.
  • 16. Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328-39.
  • 17. Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PDL1) expression in patients with non-small cell lung cancer: A meta-analysis. J Thorac Dis. 2015;7:462-70.
  • 18. Chen YY, Wang LB, Zhu HL, Li XY, Zhu YP, Yin YL, Lü FZ, Wang ZL, Qu JM. Relationship between programmed deathligand 1 and clinicopathological characteristics in non-small cell lung cancer patients. Chin Med Sci J. 2013;28:147-51.
  • 19. Azuma K, Ota K, Kawahara A, Hattori S, Iwama E, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmallcell lung cancer. Ann Oncol. 2014;25:1935-40.
  • 20. Mu CY, Huang JA, Chen Y, Chen C, Zhang XG. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682- 8.
  • 21. Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L, Rimm DL. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest. 2014;94:107-16.
  • 22. Kawahara T, Ishiguro Y, Ohtake S, Kato I, Ito Y, Ito H, Makiyama K, Kondo K, Miyoshi Y, Yumura Y, Hayashi N, Hasumi H, Osaka K, Muraoka K, Izumi K, Teranishi JI, Uemura H, Yao M, Nakaigawa N. PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer. BMC Urol. 2018;18:97.
  • 23. Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, Midha A, Walker J. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200-15.
  • 24. Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N. Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol. 2015;3:217-21.
  • 25. Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y, Zhang Q, Zhang F, Liu H, Li T, Sugimura H, Cappuzzo F, Lin D, Lv T. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: A meta-analysis of 50 studies with 11,383 patients. Transl Lung Cancer Res. 2019;8:429-49.
  • 26. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, Xu Y, Fan J. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15:971-9.
  • 27. Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, Dolled- Filhart M, Emancipator K, Wu D, Weiner R, Frisman D, Kim HK, Choi YS, Shim YM, Kim J. Prognostic significance of PD-L1 in patients with non-small cell lung cancer: A large cohort study of surgically resected cases. J Thorac Oncol. 2016;11:1003-11. 28. Schildhaus HU. Predictive value of PD-L1 diagnostics. Pathologe. 2018;39:498-519.
  • 29. Zhang H, Zhang DX, Ju T, Zhou J. The effect of postoperative radiotherapy on the survival of patients with resectable stage III-N2 non-small-cell lung cancer: A systematic review and meta-analysis. Neoplasma. 2019;66:717-726.
  • 30. Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada R, Higgins JP, Johnson DH, Van Meerbeeck J, Parmar MK, Souhami RL, Bergman B, Douillard JY, Dunant A, Endo C, Girling D, Kato H, Keller SM, Kimura H, Knuuttila A, Kodama K, Komaki R, Kris MG, Lad T, Mineo T, Piantadosi S, Rosell R, Scagliotti G, Seymour LK, Shepherd FA, Sylvester R, Tada H, Tanaka F, Torri V, Waller D, Liang Y. Adjuvant chemotherapy for resected earlystage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;(3):CD011430.
  • 31. O’Mahony S, Nathan S, Mohajer R, Bonomi P, Batus M, Fidler MJ, Wells K, Kern N, Sims S, Amin D. survival prediction in ambulatory patients with stage III/IV non-small cell lung cancer using the palliative performance scale, ECOG, and Lung cancer symptom scale. Am J Hosp Palliat Care. 2016;33:374-80.
APA ARAK H, AYTEKIN A, OZKAN M, CANOZ O (2021). Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. , 239 - 248. 10.5146/tjpath.2021.01545
Chicago ARAK HACI,AYTEKIN Aydın,OZKAN Metin,CANOZ Ozlem Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. (2021): 239 - 248. 10.5146/tjpath.2021.01545
MLA ARAK HACI,AYTEKIN Aydın,OZKAN Metin,CANOZ Ozlem Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. , 2021, ss.239 - 248. 10.5146/tjpath.2021.01545
AMA ARAK H,AYTEKIN A,OZKAN M,CANOZ O Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. . 2021; 239 - 248. 10.5146/tjpath.2021.01545
Vancouver ARAK H,AYTEKIN A,OZKAN M,CANOZ O Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. . 2021; 239 - 248. 10.5146/tjpath.2021.01545
IEEE ARAK H,AYTEKIN A,OZKAN M,CANOZ O "Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience." , ss.239 - 248, 2021. 10.5146/tjpath.2021.01545
ISNAD ARAK, HACI vd. "Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience". (2021), 239-248. https://doi.org/10.5146/tjpath.2021.01545
APA ARAK H, AYTEKIN A, OZKAN M, CANOZ O (2021). Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. Türk Patoloji Dergisi, 37(3), 239 - 248. 10.5146/tjpath.2021.01545
Chicago ARAK HACI,AYTEKIN Aydın,OZKAN Metin,CANOZ Ozlem Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. Türk Patoloji Dergisi 37, no.3 (2021): 239 - 248. 10.5146/tjpath.2021.01545
MLA ARAK HACI,AYTEKIN Aydın,OZKAN Metin,CANOZ Ozlem Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. Türk Patoloji Dergisi, vol.37, no.3, 2021, ss.239 - 248. 10.5146/tjpath.2021.01545
AMA ARAK H,AYTEKIN A,OZKAN M,CANOZ O Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. Türk Patoloji Dergisi. 2021; 37(3): 239 - 248. 10.5146/tjpath.2021.01545
Vancouver ARAK H,AYTEKIN A,OZKAN M,CANOZ O Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience. Türk Patoloji Dergisi. 2021; 37(3): 239 - 248. 10.5146/tjpath.2021.01545
IEEE ARAK H,AYTEKIN A,OZKAN M,CANOZ O "Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience." Türk Patoloji Dergisi, 37, ss.239 - 248, 2021. 10.5146/tjpath.2021.01545
ISNAD ARAK, HACI vd. "Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience". Türk Patoloji Dergisi 37/3 (2021), 239-248. https://doi.org/10.5146/tjpath.2021.01545